<DOC>
	<DOCNO>NCT01090661</DOCNO>
	<brief_summary>To assess electrocardiogram ( ECG ) effect mipomersen administer 200-mg subcutaneous ( SC ) therapeutic 200-mg intravenous ( IV ; [ 2-hour infusion ] ) supra-therapeutic dose relative placebo healthy adult male female subject ; evaluate safety pharmacokinetics ( PK ) mipomersen administer single therapeutic ( 200 mg ) SC single , supra-therapeutic ( 200 mg ) IV dose .</brief_summary>
	<brief_title>A Study Evaluate Effect Mipomersen Cardiac Repolarization Conducted Healthy Subjects</brief_title>
	<detailed_description>This randomize , double-blind , single-site , crossover study healthy male female subject determine mipomersen administered single therapeutic ( 200 mg ) SC single supra-therapeutic ( 200 mg ) IV dose delay cardiac repolarization determine measurement QT/corrected QT ( QTc ) interval . A total 60 healthy male female subject enrol 4-way crossover study , randomly assign 1 8 treatment sequence , cross 4 treatment period subject receive single SC injection single IV infusion period .</detailed_description>
	<mesh_term>Mipomersen</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Written inform consent provide studyrelated procedure perform . Body mass index ( BMI ) 19 32 kg/m2 inclusive . Subjects consume nicotine nicotinecontaining product least 6 month Screening . Subjects nonpregnant nonlactating , surgically sterile , postmenopausal , abstinent , subject partner willing use reliable method contraception study 5 month last dose investigational product . History risk factor Torsades de Pointes , know Long QT Syndrome , heart failure , myocardial infarction , angina , clinically significant abnormal laboratory assessment family history Long QT Brugada Syndrome . Abnormal screen ECG interpret Investigator clinically significant . Use concomitant medication ( prescribed overthecounter ) , without approval Investigator Sponsor , within 7 day first dose investigational product . Clinically significant abnormal finding physical examination , ECG , blood pressure , heart rate , medical history , clinical laboratory result Screening dose . History clinically significant allergy hematological , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurological disease . Positive test HIV antibody , hepatitis C antibody , hepatitis B surface antigen . Positive test drug abuse , alcohol , cotinine Screening dose history drug alcohol abuse dependence within 1 year Screening . History cancer , exception basal cell carcinoma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>antisense</keyword>
	<keyword>ApoB ( Apolipoprotein B )</keyword>
	<keyword>LDL ( low density lipoprotein )</keyword>
	<keyword>thorough QT</keyword>
</DOC>